TW201806592A - 治療癌症的方法 - Google Patents

治療癌症的方法 Download PDF

Info

Publication number
TW201806592A
TW201806592A TW106121574A TW106121574A TW201806592A TW 201806592 A TW201806592 A TW 201806592A TW 106121574 A TW106121574 A TW 106121574A TW 106121574 A TW106121574 A TW 106121574A TW 201806592 A TW201806592 A TW 201806592A
Authority
TW
Taiwan
Prior art keywords
cancer
foregoing
compound
formula
pharmaceutically acceptable
Prior art date
Application number
TW106121574A
Other languages
English (en)
Chinese (zh)
Inventor
李嘉強Ｊ
威 李
華多 歐圖桑
馬修 希創
尤際 李
Original Assignee
波士頓生醫公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 波士頓生醫公司 filed Critical 波士頓生醫公司
Publication of TW201806592A publication Critical patent/TW201806592A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106121574A 2016-06-28 2017-06-28 治療癌症的方法 TW201806592A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662355410P 2016-06-28 2016-06-28
US62/355,410 2016-06-28
US201762506929P 2017-05-16 2017-05-16
US62/506,929 2017-05-16
US201762514059P 2017-06-02 2017-06-02
US62/514,059 2017-06-02

Publications (1)

Publication Number Publication Date
TW201806592A true TW201806592A (zh) 2018-03-01

Family

ID=59325662

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106121574A TW201806592A (zh) 2016-06-28 2017-06-28 治療癌症的方法

Country Status (4)

Country Link
JP (1) JP2019519573A (fr)
CA (1) CA3029596A1 (fr)
TW (1) TW201806592A (fr)
WO (1) WO2018005444A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074485A (zh) * 2018-03-16 2020-12-11 小利兰·斯坦福大学托管委员会 癌症治疗反应分析

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501436A (ja) * 2018-09-18 2022-01-06 １グローブ バイオメディカル カンパニー， リミテッド 非アルコール性脂肪性肝疾患に対する処置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537640A (ja) 2007-08-27 2010-12-09 ボストン バイオメディカル， インコーポレイテッド マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
CA2736177A1 (fr) 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions d'inhibiteurs de kinase et leur utilisation pour le traitement du cancer et d'autres maladies liees aux kinases
PL2200431T3 (pl) 2007-09-10 2017-01-31 Boston Biomedical Inc Nowe kompozycje i metody służące leczeniu raka
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
AU2011227022C1 (en) 2010-03-19 2016-04-21 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
JP2014511384A (ja) 2011-03-04 2014-05-15 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッド 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
MX2015011456A (es) 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
CA2983468A1 (fr) * 2015-04-27 2016-11-03 Boston Biomedical, Inc. Composes de stat3 comme inhibiteurs de kinase pour le traitement du cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112074485A (zh) * 2018-03-16 2020-12-11 小利兰·斯坦福大学托管委员会 癌症治疗反应分析

Also Published As

Publication number Publication date
JP2019519573A (ja) 2019-07-11
WO2018005444A3 (fr) 2018-02-15
CA3029596A1 (fr) 2018-01-04
WO2018005444A2 (fr) 2018-01-04

Similar Documents

Publication Publication Date Title
JP6974669B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
Linch et al. Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
RU2745678C2 (ru) Способы лечения рака
RU2747788C2 (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
JP6768682B2 (ja) メラノーマの処置に使用するためのアピリモド
JP2022145800A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
US20180085341A1 (en) Methods for treating cancer
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
JP2020169222A (ja) 癌を治療するための方法
US20180333385A1 (en) Methods for treating cancer
JP2019518048A (ja) がんの予防および／または治療のための化合物、組成物および方法
KR20220143154A (ko) 네라티닙을 이용한 유방암의 치료법
JP2020515582A (ja) 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート
TW201731500A (zh) 用於治療癌症的方法
US20210330612A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
US20180098959A1 (en) Methods for treating cancer
TW201806592A (zh) 治療癌症的方法
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
WO2021242547A1 (fr) Belvarafenib à utiliser dans le traitement du cancer
JP2016008215A (ja) がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
WO2020074010A1 (fr) Solution de nouvelle association pour le traitement du cancer réfractaire à une chimiothérapie
WO2021114089A1 (fr) Procédés d'utilisation de crocétine dans le traitement de tumeurs solides
TW202332431A (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
Alimova et al. ATRT-07. AN EPIGENOME DIRECTED FUNCTIONAL GENOMIC SCREEN IDENTIFIES SIRT2 AS A SYNTHETIC LETHAL TARGET IN SMARCB1 DEFICIENT ATRT